Back to Explorer

Biological Indicator (BI) Premarket Notification [510(k)] Submissions : Guidance for Industry and FDA Staff

FinalCenter for Devices and Radiological Health10/04/2007

Description

FDA regulates biological indicators (BI) intended to monitor sterilizers used in health care facilities as class II medical devices requiring premarket notification (510(k)). 21 CFR 880.2800(a).This guidancedocument provides information that will help manufacturers prepare 510(k)s for BIs used with conventional sterilization methods. FDA believes that providing this information will promote a consistent and efficient regulatory process.

Scope & Applicability

Product Classes

3
Class II medical device

Biological indicators are regulated as class II medical devices

Biological Indicator

Microbiological test system providing a defined resistance to a specified sterilization process; Guidance for premarket notification submissions of BIs; Subject of the premarket notification 510(k) submission

Chemical Indicator

System that reveals change in process variables based on chemical or physical change

Stakeholders

1
Health care provider

Prescribing professional who does not need to intervene for interchangeable substitution

Regulatory Context

Attributes

6
Shelf Life

Determined based on stability data; Established through stability testing; also called dating period.; Established through formal stability studies; Establishing the period during which a drug product is expected to remain within specifications; Period for drug products; The period during which a drug product is expected to remain within specifications; Duration product remains within acceptance criteria; Period during which product remains within specifications; Established for intermediates pu

Incubation period

Standard seven or more days for BIs

Shelf-life

intended storage conditions throughout the proposed shelf-life

D-value

Time required to destroy 90 percent of the vegetative cells or spores at a given temperature

Z-value

Temperature increase required to reduce D-value.

Sterility Assurance Level

Quality parameter that must remain unchanged for the policy

Related CFR Sections (3)

Related Warning Letters (10)

  • CGMP/QSR/Medical Devices/Adulterated

    Envoy Medical Inc.

    2025-12-09
  • CGMP/QSR/Medical Devices/Adulterated

    Hong Qiangxing Shenzhen Electronics Limited

    2025-11-25
  • CGMP/QSR/Medical Devices/Adulterated

    Spectra Therapy, LLC

    2025-08-12
  • CGMP/QSR/Medical Devices/Adulterated

    Mectronic Medicale S.R.L.

    2025-08-05
  • CGMP/QSR/Medical Devices/Adulterated

    Aju Pharm Co., Ltd.

    2025-06-24
  • CGMP/QSR/Medical Devices/Adulterated

    Sedecal S.A.

    2025-05-27
  • CGMP/QSR/Medical Devices/Adulterated

    NeuroSync, Inc.

    2025-05-20
  • Noah Medical Corporation

    2025-04-22
  • CGMP/QSR/Medical Devices/Adulterated

    EpiCare Acquisitions, LLC

    2025-04-08
  • Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device

    Exer Labs, Inc.

    2025-03-25

See Also (8)